Postpartum Glucose Tolerance With Levonorgesterel IUD Use in Women With Recent Gestational Diabetes

Overview

The study is being done in order to gain information on the most suitable types of birth control in women who recently had gestational diabetes, or diabetes diagnosed during pregnancy. The intrauterine device (IUD) is a highly effective form of birth control. It is inserted into the uterus and prevents pregnancy for either 5 or 10 years, depending on the type of IUD (hormone-releasing or copper). The hormone-releasing IUD works for 5 years and releases a hormone called a progestin into the uterus. The copper IUD contains no hormones and works for 10 years. The IUD is an excellent form of birth control postpartum, but it is unknown if the hormone-releasing IUD will affect blood sugars and increase a woman's risk of becoming diabetic when she's not pregnant. The hypothesis is that the hormone-containing IUD will NOT increase blood sugars, so women who use the hormone-containing IUD will have similar blood sugars to those who use the copper IUD or have had their tubes tied (no hormones).

Full Title of Study: “Postpartum Glucose Tolerance in Women With Recent Gestational Diabetes Using the Levonorgestrel IUD and Non-Hormonal Contraception: A Prospective Cohort Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2014

Interventions

  • Device: Mirena (Levonorgestrel IUD)
    • Release of intrauterine levonorgestrel for contraception, approved for up to 5 years’ use
  • Device: Paragard (Copper IUD ) or Tubal Ligation
    • Copper IUD placed to provide contraception for up to 10 years

Arms, Groups and Cohorts

  • Levonorgestrel IUD
  • Copper IUD or Tubal Ligation

Clinical Trial Outcome Measures

Primary Measures

  • Glucose tolerance at 12 months postpartum.
    • Time Frame: 12 months

Participating in This Clinical Trial

Inclusion Criteria

1. Age 18-45 years at the time of enrollment 2. Single gestation in the current pregnancy 3. GDM in the current pregnancy, diagnosed by 2- or 3-hour oral glucose tolerance test (OGTT) performed at 24-32 weeks gestation 4. Desires intrauterine contraception or tubal ligation postpartum 5. Willing and able to read and sign an informed consent form in English 6. Willing to comply with the study protocol Exclusion Criteria:

1. History of pre-gestational DM, type 1 or 2 2. Pregnancy conceived with assisted reproductive technologies 3. Positive for human immunodeficiency virus (HIV) infection 4. Desires repeat pregnancy within the first 12 months following delivery

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Northwestern University
  • Collaborator
    • Society of Family Planning
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jessica Kiley, Prinicipal Investigator – Northwestern University
  • Overall Official(s)
    • Jessica W Kiley, MD, MPH, Principal Investigator, Northwestern Universeity

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.